<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management - children and young people | Management | Diabetes - type 2 | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the primary care management of children and young people with type 2 diabetes."/><meta data-react-helmet="true" property="og:description" content="Covers the primary care management of children and young people with type 2 diabetes."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/diabetes-type-2/management/management-children-young-people/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management - children and young people | Management | Diabetes - type 2 | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/diabetes-type-2/management/management-children-young-people/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Diabetes - type 2</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management - children and young people</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/diabetes-type-2/","name":"Diabetes - type 2"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/diabetes-type-2/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management - children and young people"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Diabetes - type 2: </span><span>Scenario: Management of children and young people with type 2 diabetes</span></h1><p class="page-header__lead"><span>Last revised in January 2021</span></p></div><p class="visually-hidden">Covers the primary care management of children and young people with type 2 diabetes.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Diabetes - type 2 chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - adults"><a aria-current="false" href="../management-adults/index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - adults</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management - children and young people"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management - children and young people</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#initial-information-advice">Initial information and advice</a><ol aria-label="Sections within Initial information and advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-422">Basis for recommendation</a></li></ol></li><li><a href="index.html#treatment-targets">Treatment targets</a><ol aria-label="Sections within Treatment targets" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-f44">Basis for recommendation</a></li></ol></li><li><a href="index.html#antidiabetic-drugs">Antidiabetic drugs</a><ol aria-label="Sections within Antidiabetic drugs" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-7b9">Basis for recommendation</a></li></ol></li><li><a href="index.html#lifestyle-advice">Lifestyle advice</a><ol aria-label="Sections within Lifestyle advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#diet">Diet</a></li><li class=""><a href="index.html#exercise-physical-activity">Exercise and physical activity</a></li><li class=""><a href="index.html#alcohol-intake">Alcohol intake</a></li><li class=""><a href="index.html#smoking-drug-misuse">Smoking and drug misuse</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4a0">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-suspected-hyperglycaemic-emergencies-dka-hhs">Managing suspected hyperglycaemic emergencies (DKA and HHS)</a><ol aria-label="Sections within Managing suspected hyperglycaemic emergencies (DKA and HHS)" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-f32">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-intercurrent-illness">Managing intercurrent illness</a><ol aria-label="Sections within Managing intercurrent illness" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#sick-day-rules">&#x27;Sick-day rules&#x27;</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-7ef">Basis for recommendation</a></li></ol></li><li><a href="index.html#screening-for-managing-complications">Screening for and managing complications</a><ol aria-label="Sections within Screening for and managing complications" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#retinopathy">Retinopathy</a></li><li class=""><a href="index.html#foot-problems">Foot problems</a></li><li class=""><a href="index.html#diabetic-kidney-disease">Diabetic kidney disease</a></li><li class=""><a href="index.html#hypertension">Hypertension</a></li><li class=""><a href="index.html#dyslipidaemia">Dyslipidaemia</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-5e8">Basis for recommendation</a></li></ol></li><li><a href="index.html#transition-to-adult-care-services">Transition to adult care services</a><ol aria-label="Sections within Transition to adult care services" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-43e">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management-children-young-people" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management-children-young-people" class="visually-hidden">Scenario: Management of children and young people with type 2 diabetes</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 152b4b11-6b74-4de4-9174-64d004afca0d --><!-- begin field 00847388-ee3a-4fbe-a379-acd900ac8bc6 --><p>From age 12 months to 17 years.</p><!-- end field 00847388-ee3a-4fbe-a379-acd900ac8bc6 --><!-- end item 152b4b11-6b74-4de4-9174-64d004afca0d --></div><section aria-labelledby="initial-information-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-information-advice">What initial information and advice should I offer a child or young person with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ac8e8a3b-c6cd-420c-b776-ff8f9462f017 --><!-- begin field 690338f5-7be8-47ec-91e1-18acc3bdef27 --><p><strong>Ensure that the child or young person has an individualized care plan, provided by a multidisciplinary paediatric diabetes team.</strong></p><ul><li>Ensure that the child and their family/carers know how to contact the specialist diabetes team and are involved in making decisions about their care.<ul><li>The child or young person may be offered home-based or inpatient management initially, depending on clinical need and family circumstances and wishes.</li></ul></li><li>Ensure that the child and their family/carers are offered a continuing programme of education, which is tailored to their individual needs, including:<ul><li>The need for HbA1c monitoring and <a class="topic-reference internal-reference" href="index.html#treatment-targets">treatment targets</a>.</li><li>The effects of <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">lifestyle</a> and <a class="topic-reference internal-reference" href="index.html#managing-intercurrent-illness">intercurrent illness</a> on blood glucose control.</li><li>The aims of treatment with <a class="topic-reference internal-reference" href="index.html#antidiabetic-drugs">antidiabetic drugs</a> and possible adverse effects.</li><li>The need for regular <a class="topic-reference internal-reference" href="index.html#screening-for-managing-complications">monitoring for complications</a> of type 2 diabetes, and how to reduce the risk. Note: this will usually be arranged by the paediatric diabetes team at diagnosis and regularly thereafter. If there is any uncertainty, seek specialist advice.</li></ul></li><li>Provide advice on sources of information and support.<ul><li>Diabetes UK (website available at <a href="https://www.diabetes.org.uk/" data-hyperlink-id="12c79d7a-5ed3-4d72-85cd-aca0010ea22e">www.diabetes.org.uk</a>) — a national charity that provides information, support, and advocacy for people with diabetes and their families. It has a confidential helpline (0345 123 2399) and hosts an online community for peer support, as well as a wide range of education and information <a href="https://www.diabetes.org.uk/professionals/information-support-for-your-patients/education-information" data-hyperlink-id="6f592ab1-35c2-4076-ad58-aca0010ea22e">patient resources</a>.</li><li>For detailed information on managing other lifestyle and cultural issues, such as driving, fasting, holiday and travel, insurance, and shift work, see the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a>.</li></ul></li><li>Assess for anxiety, depression, emotional and behavioural difficulties, and eating disorders, and offer emotional and psychosocial support as needed. See the CKS topics on <a class="topic-reference external-reference" href="../../../depression-in-children/index.html">Depression in children</a>, <a class="topic-reference external-reference" href="../../../conduct-disorders-in-children-young-people/index.html">Conduct disorders in children and young people</a>, and <a class="topic-reference external-reference" href="../../../eating-disorders/index.html">Eating disorders</a> for more information.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/emotions" data-hyperlink-id="243379d2-bb94-4e19-927b-aca1011426cd">Diabetes and your emotions</a> may be helpful.</li></ul></li><li>Advise about sexual health, contraception, and the importance of pre-pregnancy counselling, if appropriate. See the CKS topics on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a> and <a class="topic-reference external-reference" href="../../../../pre-conception-advice-and-management.html">Pre-conception - advice and management</a> for more information.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/pregnancy" data-hyperlink-id="3cccaeca-f21c-47a1-8980-aca1011426cd">Planning for a pregnancy when you have diabetes</a> may be helpful.</li></ul></li><li>Offer immunization against influenza (if over the age of 6 months) and pneumococcal infection (if needing oral antidiabetic drugs or insulin). See the CKS topics on <a class="topic-reference external-reference" href="../../../immunizations-seasonal-influenza/index.html">Immunizations - seasonal influenza</a> and <a class="topic-reference external-reference" href="../../../immunizations-pneumococcal/index.html">Immunizations - pneumococcal</a> for more information.</li><li>Measure height and weight, calculate body mass index (BMI), and plot on an appropriate growth chart.<ul><li>Check for normal growth and/or significant changes in weight, as these may reflect changes in blood glucose control.</li></ul></li><li>Advise the person to always wear or carry some form of diabetes identification, such as a:<ul><li>MedicAlert® bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="a38fa5f2-eb5d-4714-ab9c-a93100c1faba">www.medicalert.org.uk</a>).</li><li>Diabetes identity card or wristband (available from <a href="https://www.diabetes.org.uk/" data-hyperlink-id="77e582d5-998c-420a-9c7f-aca0010ea22e">www.diabetes.org.uk</a>).</li></ul></li></ul><!-- end field 690338f5-7be8-47ec-91e1-18acc3bdef27 --><!-- end item ac8e8a3b-c6cd-420c-b776-ff8f9462f017 --></div><section aria-labelledby="basis-for-recommendation-422" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-422">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 42287caa-0ec8-49b6-9710-4c818ada5925 --><!-- begin field e9a13a81-048d-4f03-8c15-bc38d9ef15d4 --><p>The recommendations on initial information and advice are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]; the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Type 2 diabetes mellitus in youth</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>], <em>Diabetes education in children and adolescents</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Phelan, 2018</a>], and <em>Diabetes in adolescence</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cameron, 2018</a>]; and expert opinion in a review article on youth-onset type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Candler, 2018a</a>].</p><ul><li>The information on the need for an individualized care plan and a structured education programme is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cameron, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Phelan, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Candler, 2018a</a>].<br><ul><li>NICE recommends that to optimize the effectiveness of care and reduce the risk of complications, the specialist diabetes team should include clinical, educational, dietetic, lifestyle, mental health, and foot care input.</li><li>CKS has extrapolated recommendations from the NICE guideline for children and young people with type 1 diabetes that the management, education, empowerment, and support offered in the first few weeks following diagnosis can have a long-term effect on the person's acceptance of the condition, and their skills and motivation in its ongoing management.</li><li>The recommendations on the core elements of an education programme are based on the consensus view of the NICE guideline development group, which focused on aspects of diabetes care to optimize health benefits and avoid harms. The ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>] and expert opinion in a review article also emphasize the importance of lifestyle change and weight loss [<a class="bibliography-reference internal-reference" href="../../references/index.html">Candler, 2018a</a>].</li><li>The ISPAD guidelines note that the onset of type 2 diabetes in young people is often a complex and rapidly progressive disease, with optimal care being provided by a specialist multidisciplinary team [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The ISPAD guidelines on diabetes education cite evidence that educational programmes in childhood have a beneficial effect on blood glucose control and psychosocial outcomes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Phelan, 2018</a>].</li></ul></li><li>The recommendation to assess for emotional and psychosocial difficulties and offer appropriate support is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Candler, 2018a</a>].<ul><li>The ISPAD guidelines note the increased risk of anxiety and depression, eating disorders, and social isolation in young people with type 2 diabetes, which may be associated with poor adherence to treatment plans.</li></ul></li><li>The recommendation to advise about contraception and pre-pregnancy counselling is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cameron, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendation to offer influenza and pneumococcal immunization is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li><li>The recommendation to check weight and monitor body mass index (BMI) is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li><li>The recommendations on wearing or carrying diabetes identification are extrapolated from the NICE recommendations for children and young people with type 1 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li></ul><!-- end field e9a13a81-048d-4f03-8c15-bc38d9ef15d4 --><!-- end item 42287caa-0ec8-49b6-9710-4c818ada5925 --></div></section></section><section aria-labelledby="treatment-targets" class="ChapterBody-module--wrapper--2HCfk "><h3 id="treatment-targets">What are the treatment targets for children and young people with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a458f77d-dbe3-4eb4-bb8f-14524a4cee63 --><!-- begin field b06a7337-f061-4103-bbb9-165079abb840 --><ul><li><strong>The rec</strong><strong>ommended HbA1c target level for children and young people with type 2 diabetes is 48 mmol/mol (6.5%) or lower, to minimize the risk of long-term <strong><a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complications</a></strong>.</strong><ul><li>Agree an individualized lowest achievable HbA1c target with each child or young person and family/carers, taking into account factors such as daily activities, individual life goals, complications, co-morbidities, and the risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a>.<ul><li>Support them to safely achieve and maintain their individually agreed HbA1c target level.</li><li>If the HbA1c level is above the ideal target, explain that any reduction in HbA1c reduces the risk of long-term complications.</li></ul></li><li>Ensure that children and young people with type 2 diabetes are offered measurement of their HbA1c level every 3 months.</li></ul></li></ul><!-- end field b06a7337-f061-4103-bbb9-165079abb840 --><!-- end item a458f77d-dbe3-4eb4-bb8f-14524a4cee63 --></div><section aria-labelledby="basis-for-recommendation-f44" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-f44">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f44f9b86-cf62-4aa9-b2db-9a194c5f1a95 --><!-- begin field 9c9edbbe-8248-4a8a-81ab-8011f67752f5 --><p>The recommendations on treatment targets are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Type 2 diabetes mellitus in youth</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</p><ul><li>The recommended target HbA1c level of 48 mmol/mol (6.5%) for children and young people is based on the NICE clinical guideline, which found no studies that met the inclusion criteria for an evidence review. It therefore based its recommendations on target treatment levels for adults with type 2 diabetes, which were felt to be safe and achievable in younger populations as well [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li><li>The recommendation on agreeing an individualized lowest achievable HbA1c target is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li><li>The information on the benefits of any reduction in HbA1c to reduce the risk of long-term complications is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. The ISPAD guidelines note that higher HbA1c levels are significantly associated with a risk of developing microalbuminuria and kidney disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendation that children and young people should be offered an HbA1c check every 3 months is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li></ul><!-- end field 9c9edbbe-8248-4a8a-81ab-8011f67752f5 --><!-- end item f44f9b86-cf62-4aa9-b2db-9a194c5f1a95 --></div></section></section><section aria-labelledby="antidiabetic-drugs" class="ChapterBody-module--wrapper--2HCfk "><h3 id="antidiabetic-drugs">Which antidiabetic drugs are available for children and young people with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 463a7076-e542-4ae5-8d4a-07b55bcbe7fc --><!-- begin field dfae6688-2a8d-4dc5-b36b-115983dd44e7 --><ul><li><strong>Antidiabetic drug treatment for children and young people with type 2 diabetes should be initiated by the multidisciplinary paediatric diabetes team.</strong></li><ul><li>Standard-release metformin should be offered from diagnosis to children and young people with type 2 diabetes, and insulin therapy may be needed in some cases. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin in type 2 diabetes</a> for more information.</li></ul></ul><!-- end field dfae6688-2a8d-4dc5-b36b-115983dd44e7 --><!-- end item 463a7076-e542-4ae5-8d4a-07b55bcbe7fc --></div><section aria-labelledby="basis-for-recommendation-7b9" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-7b9">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7b911cdf-579a-4a9d-a8e6-5be4bd745930 --><!-- begin field ab6eadc5-d33a-48dc-943c-376b110a56e2 --><p>The recommendations on antidiabetic drugs are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Type 2 diabetes mellitus in youth</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>], and expert opinion in a review article on youth-onset type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Candler, 2018a</a>].</p><ul><li>The recommendation that antidiabetic drug treatment should be initiated by the multidisciplinary paediatric diabetes team is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].<ul><li>NICE found good-quality evidence that treatment with metformin resulted in a clinically significant improvement in blood glucose control and was associated with significantly less frequent need for emergency treatment, in most children and young people with type 2 diabetes.</li></ul></li><li>The ISPAD guidelines note that initial treatment of children and young people should include metformin and/or insulin alone or in combination, depending on symptoms, severity of hyperglycaemia, and presence or absence of ketosis/ketoacidosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>Expert opinion in a review article notes that evidence for the treatment of type 2 diabetes in children and young people is limited, therefore management recommendations are often extrapolated from study data in adults [<a class="bibliography-reference internal-reference" href="../../references/index.html">Candler, 2018a</a>].</li></ul><!-- end field ab6eadc5-d33a-48dc-943c-376b110a56e2 --><!-- end item 7b911cdf-579a-4a9d-a8e6-5be4bd745930 --></div></section></section><section aria-labelledby="lifestyle-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="lifestyle-advice">What lifestyle advice should I give a child or young person with type 2 diabetes?</h3><section aria-labelledby="diet" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diet">Diet</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 73a473d3-7d47-4821-85c8-f8cfd8d71ad5 --><!-- begin field 0984ca3a-571d-427f-860a-09395a9724ca --><p><strong>Ensure the child or young person has been offered appropriate, individualized, and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.</strong></p><ul><li><strong>Emphasize the importance of a healthy, balanced diet:</strong><ul><li>Encourage the child or young person to eat at least 5 portions of fruit and vegetables each day.</li><li>Encourage high fibre, low-glycaemic-index sources of carbohydrate (such as fruit, vegetables, wholegrains, and pulses), low-fat dairy products, and oily fish.</li><li>Portion sizes should be appropriate for age, stage of growth, and energy requirements.</li><li>Advise controlling the intake of foods containing saturated and trans-fatty acids, high-sugar drinks, and foods high in salt content.</li><li>Emphasize the importance of meal-time routines and to minimize snacking.</li><li>The Diabetes UK patient resources <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/whats-your-healthy-weight/lose-weight" data-hyperlink-id="e89a1e60-a659-47b8-9805-aca10114f0fc">Weight loss and diabetes</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/what-is-a-healthy-balanced-diet" data-hyperlink-id="2e53272c-402a-4a6a-b4fd-aca101158c4a">What is a healthy, balanced diet for diabetes?</a> may be helpful.</li></ul></li><li><strong>Offer dietary advice with other aspects of lifestyle modification, such as <a class="topic-reference internal-reference" href="index.html#exercise-physical-activity">exercise</a> and weight loss, as appropriate.</strong></li></ul><!-- end field 0984ca3a-571d-427f-860a-09395a9724ca --><!-- end item 73a473d3-7d47-4821-85c8-f8cfd8d71ad5 --></div></section><section aria-labelledby="exercise-physical-activity" class="ChapterBody-module--wrapper--2HCfk "><h4 id="exercise-physical-activity">Exercise and physical activity</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5e5b5d01-8b84-4318-b93e-0e4f4d300a54 --><!-- begin field f1b3871f-ad8c-4d2b-825b-10486722aded --><ul><li><strong>Provide information on regular exercise and physical activity.</strong> <ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/exercise" data-hyperlink-id="57669314-88b0-4d1c-b2d7-aca1011eab2c">Diabetes and exercise</a> provides helpful information on the type and duration of recommended exercise.</li><li>Aim to minimize time spent being sedentary.</li><li>Advise that regular exercise may lower blood glucose levels, improve cardiovascular risk, and reduce excess weight (when combined with a <a class="topic-reference internal-reference" href="index.html#diet">healthy diet</a>).</li></ul></li><li><strong>Provide information on the following (if appropriate):</strong><ul><li>The potential interaction of exercise and alcohol. Advise seeking advice from their specialist diabetes team if they wish to participate in a sport that may have particular risks for people with diabetes.</li><li>The effect of exercise on blood glucose levels when insulin levels are adequate (risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a>). </li><li>The effect of exercise on blood glucose levels when the person is hyperglycaemic (risk of worsening blood glucose control and ketones in the blood).</li><li>The appropriate adjustments of insulin dosage and/or nutritional intake for exercise and post-exercise periods. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin in type 2 diabetes</a> for more information.</li></ul></li></ul><!-- end field f1b3871f-ad8c-4d2b-825b-10486722aded --><!-- end item 5e5b5d01-8b84-4318-b93e-0e4f4d300a54 --></div></section><section aria-labelledby="alcohol-intake" class="ChapterBody-module--wrapper--2HCfk "><h4 id="alcohol-intake">Alcohol intake</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 46eb85ba-c221-4099-9ab5-d010ec216878 --><!-- begin field 06605f98-1614-43b5-be83-39dcf49e8cf2 --><ul><li><strong>Provide information on recommended alcohol limits and the potential impact of alcohol on diabetes and its treatment.</strong><ul><li>Provide information that the legal drinking age in the UK is 18 years and advise on the recommended alcohol limits.<ul><li>The national charity Drinkaware (website available at <a href="https://www.drinkaware.co.uk/" data-hyperlink-id="90c22ef5-4dec-4a9b-a824-aca3010ce6d8">www.drinkaware.co.uk</a>) has useful information on <a href="https://www.drinkaware.co.uk/facts/alcohol-and-the-law/the-law-on-alcohol-and-under-18s" data-hyperlink-id="9ba82608-bd9e-47a5-a3e6-aca3010ce6d8">The law on alcohol and under 18s</a>.</li></ul></li><li>Advise the person to ideally eat a snack that contains carbohydrate before and after drinking alcohol. </li><li>Educate that alcohol may exacerbate or prolong the hypoglycaemic effect of insulin therapy.<ul><li>The signs of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a> may become less obvious, and delayed hypoglycaemia may occur up to several hours after alcohol consumption. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information on the possible presentation and effects of hypoglycaemia. </li></ul></li><li>Advise the person to always wear or carry some form of diabetes identification, as reduced awareness of hypoglycaemia may be confused with alcohol intoxication, such as a:<ul><li>MedicAlert® bracelet, necklace, or watch (available from <a href="http://www.medicalert.org.uk/" data-hyperlink-id="a38fa5f2-eb5d-4714-ab9c-a93100c1faba">www.medicalert.org.uk</a>).</li><li>Diabetes identity card or wristband (available from <a href="https://www.diabetes.org.uk/" data-hyperlink-id="77e582d5-998c-420a-9c7f-aca0010ea22e">www.diabetes.org.uk</a>).</li></ul></li><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/what-to-drink-with-diabetes/alcohol-and-diabetes" data-hyperlink-id="501c9556-7c37-4851-aac4-aca101432e59">Alcohol and diabetes</a> may be helpful.</li></ul></li></ul><!-- end field 06605f98-1614-43b5-be83-39dcf49e8cf2 --><!-- end item 46eb85ba-c221-4099-9ab5-d010ec216878 --></div></section><section aria-labelledby="smoking-drug-misuse" class="ChapterBody-module--wrapper--2HCfk "><h4 id="smoking-drug-misuse">Smoking and drug misuse</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 821d4070-8c91-4d29-9475-c273721f17de --><!-- begin field c4a3dc5f-f979-426d-b831-5791107faae9 --><ul><li><strong>Provide information on the impact of smoking on diabetes and its complications, such as cardiovascular disease.</strong><ul><li>Advise on smoking cessation, if appropriate. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information.</li><li>Advise young people who are non-smokers never to start smoking.</li></ul></li><li><strong>Provide information on the risks of drug misuse and the possible effects on blood glucose control.</strong><ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/young-adults/drugs" data-hyperlink-id="2a0d660b-8822-4d73-aede-aca10142cf61">Recreational drugs and diabetes</a> may be helpful.</li></ul></li></ul><!-- end field c4a3dc5f-f979-426d-b831-5791107faae9 --><!-- end item 821d4070-8c91-4d29-9475-c273721f17de --></div></section><section aria-labelledby="basis-for-recommendation-4a0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4a0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4a037ec4-cd56-48e7-b4ea-a2906d38b5b4 --><!-- begin field b7968099-7598-48ef-9663-3e718f630c03 --><p>The recommendations on lifestyle advice are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], and the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Type 2 diabetes mellitus in youth</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>], <em>Nutritional management in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>], and <em>Exercise in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>].</p><h5>Advice on diet</h5><ul><li>The recommendation to ensure referral to a paediatric dietitian is extrapolated from the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendations on the importance of a healthy, balanced diet are based on the clinical experience and consensus opinion of the NICE guideline development group [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>]. Together they note potential benefits include reduced blood glucose levels, reduced cardiovascular risk, and weight loss.<ul><li>The recommendation to eat at least 5 portions of fruit and vegetables each day is based on the NICE guideline.</li><li>The information on appropriate portion sizes is based on the ISPAD consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The ISPAD consensus guidelines recommend reduced carbohydrate and saturated fat intake, increased fibre intake, and reduced high-sugar drinks [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendation on meal-time routines and snacking is based on the ISPAD guidelines on nutrition, as these measures aim to improve food quality and optimize blood glucose control [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>].</li></ul></li><li>The ISPAD clinical practice consensus guidelines note that weight loss improves insulin resistance and blood glucose levels [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>]. Similarly, the ISPAD guidelines on nutrition highlights the aim to maintain an ideal body weight and optimize growth and development, to prevent acute and chronic complications of type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>].</li></ul><h5>Advice on exercise and physical activity</h5><ul><li>The ISPAD clinical practice consensus guidelines note that regular exercise has been shown to improve insulin resistance, blood glucose control, reduce cardiovascular disease risk factors, contribute to weight loss, and improve wellbeing [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].<ul><li>These guidelines recommend regular daily exercise, and to minimize time spent being sedentary.</li></ul></li><li>In addition, the ISPAD clinical practice consensus guidelines on exercise note further potential benefits of increasing metabolic rate, reducing blood pressure, reducing LDL-cholesterol and increasing HDL, and reducing the risk of cardiovascular morbidity and mortality [<a class="bibliography-reference internal-reference" href="../../references/index.html">Adolfsson, 2018</a>].</li></ul><h5>Advice on alcohol intake</h5><ul><li>The recommendations on reducing the risks of alcohol for people with type 2 diabetes have been extrapolated from the NICE recommendations on alcohol intake for children and young people with type 1 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. They are also pragmatic, based on what CKS considers to be safe clinical practice.<ul><li>In addition, the ISPAD clinical practice consensus guidelines note that misuse of alcohol increases the risks of fatty liver disease and hypoglycaemia in some children [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li></ul></li></ul><h5>Advice on smoking and drug misuse</h5><ul><li>The information on the risks of smoking and advice on smoking cessation is based on the NICE guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendations on drug misuse are pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field b7968099-7598-48ef-9663-3e718f630c03 --><!-- end item 4a037ec4-cd56-48e7-b4ea-a2906d38b5b4 --></div></section></section><section aria-labelledby="managing-suspected-hyperglycaemic-emergencies-dka-hhs" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-suspected-hyperglycaemic-emergencies-dka-hhs">How should I manage a child or young person with a suspected hyperglycaemic emergency?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d7800596-b005-482b-81b6-13a9bd4ec2cb --><!-- begin field 97ff8745-ed8a-495a-92ec-e0c2a63e5660 --><p><strong>Be aware that </strong><strong><a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">diabetic ketoacidosis</a></strong><strong> (DKA) is more common in people with type 1 diabetes, but can occur in people with type 2 diabetes, and may present with a normal or near normal blood glucose level. </strong><strong><a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">Hyperosmolar hyperglycaemic state</a></strong><strong> (HHS) typically presents without significant blood or urinary ketones on testing.</strong></p><ul><li><strong>Arrange emergency admission to a hospital with acute paediatric facilities, for confirmation of the diagnosis and emergency treatment.</strong></li><li><strong>After the child or young person has recovered from an episode of DKA or HHS:</strong><ul><li>Discuss the <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html#precipitating-factors">precipitating factors</a> that may have led to the episode. Consider the possibility of non-adherence to treatment, particularly if there is a history of recurrent DKA.</li><li>Provide information and advice about how to manage intercurrent illness and 'sick-day rules', to reduce the risk of future episodes. See the section on <a class="topic-reference internal-reference" href="index.html#managing-intercurrent-illness">Managing intercurrent illness</a> for more information.</li></ul></li></ul><!-- end field 97ff8745-ed8a-495a-92ec-e0c2a63e5660 --><!-- end item d7800596-b005-482b-81b6-13a9bd4ec2cb --></div><section aria-labelledby="basis-for-recommendation-f32" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-f32">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f32fdf3c-4791-4d30-9d2c-e7f92eeebdda --><!-- begin field 5a64f6c4-70c1-4bab-9009-f20d5f045d1d --><p>The recommendations on management of suspected hyperglycaemic emergencies are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]; the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Diabetic ketoacidosis and the hyperglycemic hyperosmolar state</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>], <em>Definition, epidemiology, and classification of diabetes in children and adolescents</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mayer-Davis, 2018</a>], and <em>Nutritional management in children and adolescents with diabetes</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>]; and expert opinion in review articles on DKA and HHS [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>] and on sick-day rules [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>].</p><ul><li>The information that diabetic ketoacidosis (DKA) may occur with normal or near normal blood glucose levels (euglycaemic DKA) is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>].</li><li>The information that hyperosmolar hyperglycaemic state (HHS) may occur without significant blood or urinary ketones is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>] and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>].</li><li>The recommendation to arrange emergency hospital admission for hyperglycaemic emergencies is based on the need for treatment with intravenous fluids to correct volume deficits and restore intravascular volume, replacement of electrolytes to correct abnormalities, correction of acidosis, and insulin infusion to treat hyperglycaemia (in the case of DKA) [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li><li>The recommendation to identify precipitating factors and prevent recurrence by managing future intercurrent illness is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Wolfsdorf, 2018</a>], and expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>]. In addition, the ISPAD clinical practice consensus guidelines on nutrition note that repeated episodes of DKA or worsening blood glucose control may be a sign of disordered eating [<a class="bibliography-reference internal-reference" href="../../references/index.html">Smart, 2018</a>].</li></ul><!-- end field 5a64f6c4-70c1-4bab-9009-f20d5f045d1d --><!-- end item f32fdf3c-4791-4d30-9d2c-e7f92eeebdda --></div></section></section><section aria-labelledby="managing-intercurrent-illness" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-intercurrent-illness">How should I manage intercurrent illness in a child or young person with type 2 diabetes?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2a4b9807-870b-4314-8e59-4e72d9e6a2d5 --><!-- begin field c93c2992-b7c1-4d1d-bc6e-73d4184ac3eb --><p><strong>If a child or young person with type 2 diabetes is unwell, consider the need to arrange hospital admission or seek specialist advice, depending on clinical judgement,</strong> taking into account the person's age, co-morbidities, risk of complications, and the presence of hyperglycaemia and/or ketosis.</p><ul><li><strong>Arrange immediate hospital admission if:</strong><ul><li>There is an immediate risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">diabetic ketoacidosis</a> (DKA), such as ketonaemia (1.5–2.9 mmol/L) with or without hyperglycaemia, and the child cannot eat or drink.</li><li>There is an immediate risk of <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">hyperosmolar hyperglycaemic state</a> (HHS).</li><li>There is suspected acute kidney injury (AKI) that cannot be managed in primary care. See the CKS topic on <a class="topic-reference external-reference" href="../../../acute-kidney-injury/index.html">Acute kidney injury</a> for more information.</li><li>A person treated with insulin does not show signs of clinical improvement with insulin treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a>.</li></ul></li><li><strong>Consider arranging hospital admission or seeking urgent specialist advice if:</strong><ul><li>The underlying condition is unclear.</li><li>The child is dehydrated or at risk of dehydration.</li><li>Vomiting persists beyond 2 hours (particularly in young children).</li><li>The child is younger than 3 years of age or has a co-existing medical condition.</li><li>The person and their family/carers are unable to keep the blood glucose level above 3.5 mmol/L.</li><li>The person and their family/carers are exhausted, for example due to repeated night-time waking.</li></ul></li><li><strong>If admission is not needed and the child or young person can be managed in primary care:</strong><ul><li>Ensure that the person or family/carers has written contact details of their specialist diabetes team.</li><li>Assess the child and manage any intercurrent illness(es), as appropriate.</li><li>Provide the person or family/carers with clear, individualized advice on <a class="topic-reference internal-reference" href="index.html#sick-day-rules">'sick-day rules'</a> to manage diabetes during episodes of intercurrent illness or hyperglycaemia, and reinforce the advice regularly.<ul><li>Advise that intercurrent illness may affect blood glucose control, and there is a risk for worsening hyperglycaemia even if dietary intake is reduced.</li></ul></li><li>Ensure the child has sick day foods and drinks supplies readily accessible at home, including:<ul><li>Easily digestible foods and sugary drinks (to provide energy and to prevent further ketosis).</li><li>Over-the-counter oral rehydration therapy (ORT) sachets (to prevent dehydration).</li><li>Glucose tablets or oral gel (to prevent hypoglycaemia).</li><li>Equipment for monitoring blood glucose and ketones (if appropriate). </li><li>Additional supplies of insulin (if appropriate).</li><li>A glucagon kit (if appropriate).</li><li>Note: see the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for information on blood glucose and ketone monitoring meters, glucose oral gels, and other accessories.</li></ul></li></ul></li></ul><!-- end field c93c2992-b7c1-4d1d-bc6e-73d4184ac3eb --><!-- end item 2a4b9807-870b-4314-8e59-4e72d9e6a2d5 --></div><section aria-labelledby="sick-day-rules" class="ChapterBody-module--wrapper--2HCfk "><h4 id="sick-day-rules">'Sick-day rules'</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2bc459ba-4a29-4e5e-9103-6fd6279f8ba4 --><!-- begin field b29e63bb-9aac-458a-90a1-f49781d3e3a9 --><ul><li><strong>Reinforce 'sick-day rules' advice on managing episodes of intercurrent illness, which should have been provided by the child's specialist diabetes team.</strong><ul><li>If on insulin therapy, do not stop treatment. See the CKS topic on <a class="topic-reference external-reference" href="../../../insulin-therapy-in-type-2-diabetes/index.html">Insulin therapy in type 2 diabetes</a> for more information.<ul><li>Advise the dose of insulin may need to be altered during periods of illness. Seek advice from the specialist diabetes team if there is uncertainty on how to adjust insulin doses.</li></ul></li><li>Consider the need for blood <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">ketone monitoring</a>, depending on advice from the specialist diabetes team.<ul><li>This should be checked regularly, for example at least every 3–4 hours including through the night and advice given to record the results.</li></ul><ul><li>If the blood ketone level is greater than 3 mmol/L, the person or family/carers should seek immediate medical advice. See the section on <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hyperglycaemic-emergencies-dka-hhs/index.html">When to suspect hyperglycaemic emergencies (DKA and HHS)</a> for more information.</li></ul></li><li>Advise to maintain their normal meal pattern (including fluids and carbohydrate intake) where possible if appetite is reduced.<ul><li>If unable to eat or vomiting, advise to replace normal meals with carbohydrate-containing drinks (such as milk, milkshakes, fruit juices, and sugary drinks).</li><li>If blood glucose levels are high, maintain fluid intake with sugar-free fluids.</li><li>If blood glucose levels are low, encourage regular intake of sugary fluids.</li></ul></li><li>Advise to seek urgent medical advice if the child:<ul><li>Is unable to eat or drink, is dehydrated or at risk of dehydration.</li><li>Has persistent vomiting.</li><li>Has <a class="topic-reference internal-reference" href="../../diagnosis/when-to-suspect-hypoglycaemia/index.html">hypoglycaemia</a> that cannot be managed in primary care.</li></ul></li><li>The Diabetes UK information <a href="https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/illness" data-hyperlink-id="6436ab8a-5ade-4dfd-9d24-aca101132cb6">Diabetes when you're unwell</a> may be helpful.</li></ul></li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>]</p><!-- end field b29e63bb-9aac-458a-90a1-f49781d3e3a9 --><!-- end item 2bc459ba-4a29-4e5e-9103-6fd6279f8ba4 --></div></section><section aria-labelledby="basis-for-recommendation-7ef" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-7ef">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7ef7eb80-f767-44e3-b749-4a2279c1ab59 --><!-- begin field f1c644e3-0e9f-4772-a23a-482172bbf266 --><p>The recommendations on managing intercurrent illness are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>], and expert opinion in review articles on DKA and HHS [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>], on diabetic reviews [<a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>], and on sick-day rules [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>].</p><h5>Arranging hospital admission or seeking specialist advice</h5><ul><li>The recommendations on arranging hospital admission or seeking specialist advice are based on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">French, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>]. They are also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Managing intercurrent illness in primary care</h5><ul><li>The recommendation to provide advice on 'sick-day rules' is extrapolated from the NICE clinical guideline advice for children and young people with type 1 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. It is also based on expert opinion in review articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Down, 2020</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Milne, 2020</a>], and is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field f1c644e3-0e9f-4772-a23a-482172bbf266 --><!-- end item 7ef7eb80-f767-44e3-b749-4a2279c1ab59 --></div></section></section><section aria-labelledby="screening-for-managing-complications" class="ChapterBody-module--wrapper--2HCfk "><h3 id="screening-for-managing-complications">How should I screen for and manage complications in children and young people with type 2 diabetes?</h3><section aria-labelledby="retinopathy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="retinopathy">Retinopathy</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 35d9fe5a-9a68-47c7-b6e9-47a2c5dca02e --><!-- begin field 9fff722e-5731-4d01-97fc-6c34d9856f16 --><p><strong>Ensure that from the age of 12 years, all children with type 2 diabetes attend for diabetic eye screening, as part of the NHS retinopathy screening programme.</strong></p><ul><li>Children should attend for an eye examination by an optometrist every 2 years until the age of 12 years.<ul><li>Children should be referred to the local retinopathy screening programme prior to their twelfth birthday, to ensure that they are seen from 12 years of age.</li><li>Consider referring children who are younger than 12 years to an ophthalmologist for retinal examination, if blood glucose control is suboptimal.</li></ul></li><li>Explain that retinal screening aims to reduce the risk of sight loss by the early detection and treatment, if needed, of sight-threatening retinopathy. Improving blood glucose control will reduce the risk of any background retinopathy detected progressing to significant diabetic retinopathy.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/diabetic-eye-screening" data-hyperlink-id="87d7cedb-8c8e-4050-8821-aca101574d92">Diabetic eye screening</a> may be helpful.</li></ul></li></ul><!-- end field 9fff722e-5731-4d01-97fc-6c34d9856f16 --><!-- end item 35d9fe5a-9a68-47c7-b6e9-47a2c5dca02e --></div></section><section aria-labelledby="foot-problems" class="ChapterBody-module--wrapper--2HCfk "><h4 id="foot-problems">Foot problems</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bed647fe-3332-43ae-b080-73bddd604d45 --><!-- begin field 7b68ce4f-51e8-42eb-b964-237a06628fc7 --><ul><li><strong>For children with type 2 diabetes who are younger than 12 years of age,</strong> explain the importance of regular foot care and give basic foot care advice:<ul><li>Explain the need to check daily the entire surface of both feet, including areas between the toes. The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/feet" data-hyperlink-id="419ece61-9ad1-4392-b86c-aca1015d5e5f">Diabetes and foot problems</a> may be helpful.</li><li>Foot emergencies and who to contact.</li><li>Footwear advice, including to avoid shoes that are too tight, have rough edges, or uneven seams; to avoid tight-fitting socks and change socks daily.</li><li>Nail-cutting advice.</li><li>How to recognize foot ulcers and pre-ulcerative signs.</li></ul></li><li><strong>For young people with type 2 diabetes aged between 12–17 years, </strong>ensure that the specialist diabetes team arrange a foot check at least once a year, or sooner if any foot problems arise.<ul><li>If a diabetic foot problem is found or suspected, referral should be arranged to an appropriate specialist.</li></ul></li></ul><!-- end field 7b68ce4f-51e8-42eb-b964-237a06628fc7 --><!-- end item bed647fe-3332-43ae-b080-73bddd604d45 --></div></section><section aria-labelledby="diabetic-kidney-disease" class="ChapterBody-module--wrapper--2HCfk "><h4 id="diabetic-kidney-disease">Diabetic kidney disease</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c22aaebd-54ec-413a-803a-05c4b34be09b --><!-- begin field 5a3d1abd-7f68-40a8-b50a-8337a0bb4263 --><p><strong>Ensure all children and young people with type 2 diabetes have annual screening for diabetic kidney disease.</strong></p><ul><li><strong>To assess for diabetic kidney disease in children:</strong><ul><li>Arrange an early morning first-void urine sample if possible, for assessment of microalbuminuria by estimation of the albumin:creatinine ratio (ACR).</li><li>Note: a random urine sample may be used, but this is associated with an increased risk of false positive results.<ul><li>If the initial urine ACR is 3–30 mg/mmol, confirm the result by repeating the test on two further occasions, using early morning first-void urine samples, before arranging further investigation or referral.</li><li>If the urine ACR is 30 mg/mmol or more, arrange further investigation or referral.</li><li>Liaise with the child's specialist diabetic team or paediatric nephrologist if there is any uncertainty about managing results.</li></ul></li></ul></li><li><strong>Advise that if microalbuminuria (urine ACR is 3–30 mg/mmol) is detected,</strong> improving blood glucose control should reduce the risk of progression to significant diabetic kidney disease.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/complications/kidneys_nephropathy" data-hyperlink-id="bcd081f4-b284-49ed-9361-aca1016244b8">Diabetic nephropathy (kidney disease)</a> may be helpful.</li></ul></li></ul><!-- end field 5a3d1abd-7f68-40a8-b50a-8337a0bb4263 --><!-- end item c22aaebd-54ec-413a-803a-05c4b34be09b --></div></section><section aria-labelledby="hypertension" class="ChapterBody-module--wrapper--2HCfk "><h4 id="hypertension">Hypertension</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4fc98c2d-4144-4f94-85e6-07dcb53d450c --><!-- begin field 581828e8-eb07-402d-b043-406f1e3efefc --><p><strong>Ensure that all children and young people with type 2 diabetes are screened for hypertension at diagnosis and then annually.</strong></p><ul><li><strong>When measuring blood pressure in a child or young person:</strong><ul><li>Use a cuff of the correct size for the person.</li><li>If repeated resting blood pressure measurements are greater than the 95th percentile for age, sex, and height, confirm a diagnosis of hypertension using 24-hour ambulatory blood pressure monitoring (ABPM) before further investigation and specialist treatment.</li><li>Seek specialist advice if antihypertensive drug treatment is being considered.</li></ul></li><li><strong>Advise that if hypertension is detected,</strong> early specialist treatment should reduce the risk of complications.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/blood-pressure" data-hyperlink-id="60ff48c9-ff30-4a1c-88bb-aca2015eec53">Diabetes and blood pressure</a> may be helpful.</li></ul></li></ul><!-- end field 581828e8-eb07-402d-b043-406f1e3efefc --><!-- end item 4fc98c2d-4144-4f94-85e6-07dcb53d450c --></div></section><section aria-labelledby="dyslipidaemia" class="ChapterBody-module--wrapper--2HCfk "><h4 id="dyslipidaemia">Dyslipidaemia</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c42ef432-1902-4b0c-8770-ad7589662517 --><!-- begin field c8cb3744-3efd-40be-a651-a0b81ba965ad --><p><strong>Ensure that all children and young people with type 2 diabetes are screened for dyslipidaemia at diagnosis once blood glucose control is achieved, and then annually.</strong></p><ul><li><div><strong>When screening for dyslipidaemia in a child or young person:</strong></div><ul><li>Ensure that total cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol, and triglyceride concentrations are measured.</li><li>Confirm dyslipidaemia using a repeat sample (fasting or non-fasting) before deciding on further management.</li><li>Seek specialist advice if lipid-lowering drug treatment is being considered.</li></ul></li><li><strong>Advise that if dyslipidaemia is detected,</strong> early specialist treatment should reduce the risk of complications.<ul><li>The Diabetes UK patient resource <a href="https://www.diabetes.org.uk/guide-to-diabetes/enjoy-food/eating-with-diabetes/managing-other-medical-conditions/cholesterol-and-diabetes" data-hyperlink-id="71542523-9657-4438-9b47-aca300b10470">Cholesterol and diabetes</a> may be helpful.</li></ul></li></ul><!-- end field c8cb3744-3efd-40be-a651-a0b81ba965ad --><!-- end item c42ef432-1902-4b0c-8770-ad7589662517 --></div></section><section aria-labelledby="basis-for-recommendation-5e8" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-5e8">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5e8f5cff-c0da-4436-94d9-416ee747acf0 --><!-- begin field 01117e44-2b11-47dc-b389-eaa6908bce5b --><p>The recommendations on screening for complications are largely based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and <em>Diabetic foot problems: prevention and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Type 2 diabetes mellitus in youth</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>], and expert opinion in a review article on youth-onset type 2 diabetes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Candler, 2018a</a>].</p><h5>Screening for retinopathy</h5><ul><li>The recommendations on retinopathy screening in children are based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].<ul><li>The NICE guideline development group reviewed evidence and drew on clinical experience to note that retinopathy requiring treatment is rare in children and young people with type 2 diabetes, but early identification of retinopathy is important to reduce the risk of sight loss. It noted that clinical discretion may be needed to decide on earlier ophthalmology referral for children at higher risk of retinopathy (for example due to suboptimal blood glucose control or long duration of disease).</li></ul></li><li>The information on the importance of retinopathy screening and optimal blood glucose control is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li></ul><h5>Screening for foot problems</h5><ul><li>The recommendations on regular foot care, annual foot checks from the age of 12 years, and need for referral are based on the NICE guideline on foot problems [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>].</li></ul><h5>Screening for diabetic kidney disease</h5><ul><li>The recommendation that children and young people with type 2 diabetes should be screened annually for diabetic kidney disease is based on the NICE guideline, which notes that if low-level albuminuria is identified early, intervention and treatment may alter disease progression, reduce the risk of chronic kidney disease (CKD), and improve outcomes [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. This approach is supported by the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendation to use a first-void urine sample if possible is based on the fact that random urine samples are associated with an increased risk of false positive results [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. The ISPAD guidelines note that 'orthostatic proteinuria' is common in adolescents [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].<ul><li>The information on the need for repeat urine testing if the urine albumin:creatinine ratio (ACR) is moderately raised is based on the NICE guideline. Similarly, the ISPAD clinical practice consensus guidelines highlight that an elevated urine ACR may be secondary to exercise, smoking, menstruation, or orthostatic hypotension, so a diagnosis of persistent microalbuminuria requires confirmation of two or three consecutive abnormal values on different days [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendations on when to arrange further investigation or referral are based on the NICE guideline.</li><li>The recommendation to liaise with a specialist team if there is uncertainty about managing results is extrapolated from the ISPAD guidelines, which recommend that ACE inhibitor therapy may be needed if the urine ACR is greater than 3 mg/mmol with elevated blood pressure. In addition, non-diabetic causes of renal disease should be considered, and a specialist nephrology opinion is needed if there is a urine ACR greater than 30 mg/mmol [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li></ul></li><li>The information that if microalbuminuria is detected, improving blood glucose control should reduce the risk of disease progression is based on the NICE guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. This is supported by the ISPAD clinical practice consensus guidelines, which note that higher levels of HbA1c are significantly associated with the risk of developing microalbuminuria and diabetic nephropathy, as well as increasing the risk of progression of pre-existing nephropathy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li></ul><h5>Screening for hypertension</h5><ul><li>The recommendation that children and young people with type 2 diabetes should be screened annually for hypertension is based on the NICE guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].<ul><li>The recommendation to use the correct size of cuff is based on the NICE clinical guideline, to reduce the likelihood of misdiagnosis. This is supported by the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendation to arrange ambulatory blood pressure monitoring (ABPM) if resting blood pressures are raised is based on the NICE clinical guideline. This approach is supported by the ISPAD guidelines, which state that blood pressure readings greater than 95th percentiles for height, sex, and age are significant [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The recommendation to seek specialist advice if drug treatment is being considered is pragmatic, based on what CKS considers to be good clinical practice.</li></ul></li><li>The information that if hypertension is detected, early treatment can reduce the risk of complications is based on the NICE guideline, which notes that hypertension is associated with long-term morbidity and mortality [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. This is supported by the ISPAD guidelines, which note that hypertension is associated with an increased risk of cardiovascular and kidney disease. Furthermore, diastolic blood pressure, duration of diabetes, and HbA1c level are risk factors for progression of pre-existing nephropathy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li></ul><h5>Screening for dyslipidaemia</h5><ul><li>The recommendation that children and young people with type 2 diabetes should be screened for dyslipidaemia at diagnosis once blood glucose is controlled and annually thereafter, is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].<ul><li>The recommendation to arrange repeat testing to confirm the diagnosis is based on the NICE guideline, to reduce the likelihood of misdiagnosis.</li><li>The recommendation to seek specialist advice if considering drug treatment is extrapolated from the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>]. CKS notes that the NICE guideline does not specify thresholds for when to start treatment or give recommendations on drug treatments or treatment targets if dyslipidaemia is identified in children. </li></ul></li><li>The information that if dyslipidaemia is detected, early treatment can reduce the risk of complications is based on the NICE guideline, which notes that dyslipidaemia is a risk factor for cardiovascular disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>].</li></ul><!-- end field 01117e44-2b11-47dc-b389-eaa6908bce5b --><!-- end item 5e8f5cff-c0da-4436-94d9-416ee747acf0 --></div></section></section><section aria-labelledby="transition-to-adult-care-services" class="ChapterBody-module--wrapper--2HCfk "><h3 id="transition-to-adult-care-services">How should I support the transition from paediatric to adult care services?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6ff99c51-7f15-41e4-9ac0-674c2b85d91f --><!-- begin field 75e27a7b-7110-44c5-b3ff-063e0308e89b --><ul><li><strong>Explain to youn</strong><strong>g people with type 2 diabetes who are preparing for transition to adult services that some aspects of diabetes care will change at transition,</strong> such as clinic time and location, and their diabetes specialist team.<ul><li>Be aware that a deterioration in blood glucose control may be seen in young people due to a variety of factors including:<ul><li>Endocrine changes leading to increased insulin resistance.</li><li>Erratic meal and exercise patterns. See the section on <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">Lifestyle advice</a> for more information.</li><li>Poor adherence to treatment regimens.</li><li>Eating disorders. See the CKS topic on <a class="topic-reference external-reference" href="../../../eating-disorders/index.html">Eating disorders</a> for more information.</li><li>Hazardous and risk-taking behaviours. See the section on <a class="topic-reference internal-reference" href="index.html#lifestyle-advice">Lifestyle advice</a> for more information.</li></ul></li><li>The Diabetes UK patient resources <a href="https://www.diabetes.org.uk/guide-to-diabetes/your-child-and-diabetes/top-teen-tips" data-hyperlink-id="d695274d-8bff-4fa5-b15a-aca30164dc24">Talking to your teenager about diabetes</a> and <a href="https://www.diabetes.org.uk/guide-to-diabetes/young-adults/moving-clinics" data-hyperlink-id="9e1b5372-72a9-4118-bcb8-aca30164dc24">Transitioning into adult diabetes clinics</a> may be helpful.</li></ul></li></ul><!-- end field 75e27a7b-7110-44c5-b3ff-063e0308e89b --><!-- end item 6ff99c51-7f15-41e4-9ac0-674c2b85d91f --></div><section aria-labelledby="basis-for-recommendation-43e" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-43e">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 43e1d6a8-93b8-4c65-95a7-46f42d1061b0 --><!-- begin field e9a5832c-30ba-4f7d-a4f1-b0d8ac5714fe --><p>The recommendations on transition to adult services is based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>] and the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines <em>Type 2 diabetes mellitus in youth</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>] and <em>Diabetes in adolescence</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cameron, 2018</a>].</p><ul><li>The NICE clinical guideline states that in young people with diabetes who are preparing for transition to adult services, clinic attendance rates may be improved by [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]:<ul><li>Allowing sufficient time for the young person to familiarize themselves with the practicalities of the transition.</li><li>Giving appropriate information and advice on what to expect following the transition.</li></ul></li><li>The ISPAD clinical practice consensus guidelines note the transition to adult care is a time of high risk of worsening of blood glucose control and adherence to treatment, and increased risk of loss of follow up [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zeitler, 2018</a>].</li><li>The information on potential reasons for deterioration in blood glucose control in young people is based on the ISPAD clinical practice consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Cameron, 2018</a>].<ul><li>These guidelines note that young people mature at different rates, and a planned co-ordinated transition to adult care should be provided at the most appropriate time for each young person.</li></ul></li></ul><!-- end field e9a5832c-30ba-4f7d-a4f1-b0d8ac5714fe --><!-- end item 43e1d6a8-93b8-4c65-95a7-46f42d1061b0 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/diabetes-type-2/management/management-children-young-people/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>